Pharming Group (PHAR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.30
- Estimate
- $0.21
- Surprise
- +46.3%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Pharming Group (PHAR) beat the $0.21 estimate with adjusted EPS of $0.30 — a large 46.3% upside surprise.
Coverage in the report window
- Pharming Q3 2026 Earnings Call Transcript — benzinga, 2026-10-27
- Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est — benzinga, 2026-10-27
- Pharming Group N.V. Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-27
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAR Buy (Wait) at 5.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +46.3% surprise compares with a -372.6% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+0.60)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Weak growth
- Below 200-MA, MA slope -7.0%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.87
- Entry target
- $11.33
- Price target
- $29.20
- Stop
- $10.54
- Upside to target
- +146.0%
- Reward-to-risk
- 9.7:1
The stock trades at 37.1× trailing but 30.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
PHAR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $840.1M
- P/E (fwd)
- 30.8
- P/E (ttm)
- 37.1
- 52-week range
- $9.11–$21.34
- Off 52-week high
- 44.4%
- RSI (14)
- 75
- Volume vs avg
- 1.45×
- Score today
- 5.4/10